Power Im sure that is with in the relm of the conversations between the FDA and Anavex. If you look at our trials from 30,000 ft Missling has selected 3 different age groups, and multiple endpoints as primary and secondary endpoints that cross many different CNS diseases between the 3 precision medicine trials. The data we are going to glean through AI is going to be absolutely remarketable!
It is very plausible if we get past the ph 2b Rett trial with good results ( Rett being the hardest due to little girls being unable to communicate difficulties with side effects ) and we see improvement in PK Ph2 that at some point our CNS “HOMEOSTASIS” story ends up with our own office space down at the FDA with a full time employee (and secretary) dedicated to nothing but expiditing this into a marketable CNS product similiar to ibuprofen for pain! Oh wait, I just realized something..... the FDA already has a person in place with their own office and secretary.... his name is Dr. Fadiran!!!!!!!
Tred
News 
Market Data 
Discover 
